Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 symbols : TAK save search
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
Published: 2022-06-27 (Crawled : 11:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.09%
H: 1.36%
C: 0.93%
ARWR | $22.33 -1.24% -1.25% 960K
|
Health Technology
|
| O: 0.55%
H: 1.01%
C: -2.68%
results phase 2
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-09-22 (Crawled : 12:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: -1.11%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: 1.81%
H: 2.1%
C: -0.32%
phase 2 vaccine phase 3 approval sars-cov-2
GammaDelta Therapeutics Initiates First-in-Human Phase 1 Trial of GDX012 for the Treatment of Acute Myeloid Leukaemia
Published: 2021-09-15 (Crawled : 13:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.6%
H: 1.01%
C: 0.89%
treatment phase 1 trial phase 2 phase 3 leukemia myeloid leukemia
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
Published: 2021-07-28 (Crawled : 15:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.42%
H: 2.14%
C: 1.72%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.04%
H: 0.38%
C: -0.32%
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: -0.19%
H: 6.93%
C: 6.54%
phase 2 approval
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
Published: 2021-02-26 (Crawled : 14:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.72%
H: 0.5%
C: -0.95%
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: 1.81%
H: 3.52%
C: 2.54%
covid phase 1 vaccine license trial phase 3 phase 2
Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda
Published: 2021-01-21 (Crawled : 15:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.97%
H: 0.62%
C: -0.63%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 0.11%
H: 9.36%
C: 6.15%
covid vaccine phase 3 phase 1 phase 2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.